Literature DB >> 23241451

Big pharma often commits corporate crime, and this must be stopped.

Peter C Gøtzsche1.   

Abstract

Mesh：

Year:  2012        PMID： 23241451     DOI： 10.1136/bmj.e8462

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  6 in total

1.  Industry involvement in continuing medical education: time to say no.

Authors:  Sheryl Spithoff
Journal:  Can Fam Physician       Date:  2014-08       Impact factor: 3.275

2.  Complaints, complainants, and rulings regarding drug promotion in the United Kingdom and Sweden 2004-2012: a quantitative and qualitative study of pharmaceutical industry self-regulation.

Authors:  Anna V Zetterqvist; Juan Merlo; Shai Mulinari
Journal:  PLoS Med       Date:  2015-02-17       Impact factor: 11.069

3.  FDAAA legislation is working, but methodological flaws undermine the reliability of clinical trials: a cross-sectional study.

Authors:  Douglas H Marin Dos Santos; Álvaro N Atallah
Journal:  PeerJ       Date:  2015-06-25       Impact factor: 2.984

4.  Priority Setting: Right Answer to a Far Too Narrow Question? Comment on "Global Developments in Priority Setting in Health".

Authors:  Ted Schrecker
Journal:  Int J Health Policy Manag       Date:  2018-01-01

5.  Biomarkers for the Rich and Dangerous: Why We Ought to Extend Bioprediction and Bioprevention to White-Collar Crime.

Authors:  Hazem Zohny; Thomas Douglas; Julian Savulescu
Journal:  Crim Law Philos       Date:  2018-08-10

6.  Pharmaceutical Industry Off-label Promotion and Self-regulation: A Document Analysis of Off-label Promotion Rulings by the United Kingdom Prescription Medicines Code of Practice Authority 2003-2012.

Authors:  Andreas Vilhelmsson; Courtney Davis; Shai Mulinari
Journal:  PLoS Med       Date:  2016-01-26       Impact factor: 11.069
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.